219 related articles for article (PubMed ID: 36935855)
1. A predictive model of polymetastatic disease from a multicenter large retrospectIve database on colorectal lung metastases treated with stereotactic ablative radiotherapy: The RED LaIT-SABR study.
Nicosia L; Franceschini D; Perrone-Congedi F; Molinari A; Gerardi MA; Rigo M; Mazzola R; Perna M; Scotti V; Fodor A; Iurato A; Pasqualetti F; Gadducci G; Chiesa S; Niespolo RM; Bruni A; Cappelli A; D'Angelo E; Borghetti P; Di Marzo A; Ravasio A; De Bari B; Sepulcri M; Aiello D; Mortellaro G; Sangalli C; Franceschini M; Montesi G; Aquilanti FM; Lunardi G; Valdagni R; Fazio I; Scarzello G; Vavassori V; Maranzano E; Maria Magrini S; Arcangeli S; Gambacorta MA; Valentini V; Paiar F; Ramella S; Di Muzio NG; Loi M; Jereczek-Fossa BA; Casamassima F; Osti MF; Scorsetti M; Alongi F
Clin Transl Radiat Oncol; 2023 Mar; 39():100568. PubMed ID: 36935855
[TBL] [Abstract][Full Text] [Related]
2. A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study.
Nicosia L; Franceschini D; Perrone-Congedi F; Casamassima F; Gerardi MA; Rigo M; Mazzola R; Perna M; Scotti V; Fodor A; Iurato A; Pasqualetti F; Gadducci G; Chiesa S; Niespolo RM; Bruni A; Alicino G; Frassinelli L; Borghetti P; Di Marzo A; Ravasio A; De Bari B; Sepulcri M; Aiello D; Mortellaro G; Sangalli C; Franceschini M; Montesi G; Aquilanti FM; Lunardi G; Valdagni R; Fazio I; Scarzello G; Corti L; Vavassori V; Maranzano E; Magrini SM; Arcangeli S; Gambacorta MA; Valentini V; Paiar F; Ramella S; Di Muzio NG; Livi L; Jereczek-Fossa BA; Osti MF; Scorsetti M; Alongi F
Radiother Oncol; 2022 Jan; 166():92-99. PubMed ID: 34748855
[TBL] [Abstract][Full Text] [Related]
3. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.
Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F
Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases.
Nicosia L; Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Bonù M; Corradini S; Tolia M; Alongi F
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2351-2358. PubMed ID: 32356176
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiotherapy (SBRT) and concomitant systemic therapy in oligoprogressive breast cancer patients.
Nicosia L; Figlia V; Ricottone N; Cuccia F; Mazzola R; Giaj-Levra N; Ricchetti F; Rigo M; Jafari F; Maria Magrini S; Girlando A; Alongi F
Clin Exp Metastasis; 2022 Aug; 39(4):581-588. PubMed ID: 35511313
[TBL] [Abstract][Full Text] [Related]
6. Total tumor volume as a predictor of survival in patients with multiple oligometastases treated with stereotactic ablative radiotherapy (SABR).
Franzese C; Vernier V; Franceschini D; Comito T; Navarria P; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Marini B; Galdieri C; Mancosu P; Tomatis S; Scorsetti M
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10495-10503. PubMed ID: 37280407
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of stereotactic ablative radiotherapy in patients with oligometastatic hepatocellular carcinoma: A phase II study.
Choi SH; Lee BM; Kim J; Kim DY; Seong J
J Hepatol; 2024 Mar; ():. PubMed ID: 38467379
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy?
Widder J; Klinkenberg TJ; Ubbels JF; Wiegman EM; Groen HJ; Langendijk JA
Radiother Oncol; 2013 Jun; 107(3):409-13. PubMed ID: 23773410
[TBL] [Abstract][Full Text] [Related]
9. Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial.
Eufemon Cereno R; Mou B; Baker S; Chng N; Arbour G; Bergman A; Liu M; Schellenberg D; Matthews Q; Huang V; Mestrovic A; Hyde D; Alexander A; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Berrang T; Bang A; Jiang W; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson RA
Radiother Oncol; 2023 May; 182():109576. PubMed ID: 36822355
[TBL] [Abstract][Full Text] [Related]
10. Patients with colorectal lung oligometastases (L-OMD) treated by dose adapted SABR at diagnosis of oligometastatic disease have better outcomes than patients previously treated for their metastatic disease.
Mihai A; Mu Y; Armstrong J; Dunne M; Beriwal S; Rock L; Thirion P; Heron DE; Bird BH; Westrup J; Murphy CG; Huq MS; McDermott R
J Radiosurg SBRT; 2017; 5(1):43-53. PubMed ID: 29296462
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcomes of stereotactic ablative body radiotherapy on oligometastases from colorectal cancer: early results of a single institution service evaluation.
Duong J; Stewart-Lord A; Nariyangadu P; Harrison M; Tsang YM
BJR Open; 2022; 4(1):20210071. PubMed ID: 36105422
[TBL] [Abstract][Full Text] [Related]
12. Survival Outcomes and Pattern of Relapse After SABR for Oligometastatic Prostate Cancer.
Mercier C; Claessens M; De Troyer B; Debacker T; Fransis K; Vandeursen H; Ost P; Dirix P
Front Oncol; 2022; 12():863609. PubMed ID: 35494057
[TBL] [Abstract][Full Text] [Related]
13. Outcome and toxicity of hypofractionated image-guided SABR for spinal oligometastases.
Billiet C; Joye I; Mercier C; Depuydt L; De Kerf G; Vermeulen P; Van Laere S; Van de Kelft E; Meijnders P; Verellen D; Dirix P
Clin Transl Radiat Oncol; 2020 Sep; 24():65-70. PubMed ID: 32642561
[TBL] [Abstract][Full Text] [Related]
14. Outcome of lung oligometastatic patients treated with stereotactic body irradiation.
Virbel G; Cox DG; Olland A; Falcoz PE; Le Fevre C; Schott R; Antoni D; Noel G
Front Oncol; 2022; 12():945189. PubMed ID: 36003767
[TBL] [Abstract][Full Text] [Related]
15. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
[TBL] [Abstract][Full Text] [Related]
16. Ablative radiation therapy to restrain everything safely treatable (ARREST): study protocol for a phase I trial treating polymetastatic cancer with stereotactic radiotherapy.
Bauman GS; Corkum MT; Fakir H; Nguyen TK; Palma DA
BMC Cancer; 2021 Apr; 21(1):405. PubMed ID: 33853550
[TBL] [Abstract][Full Text] [Related]
17. Oligometastatic Disease (OMD): The Classification and Practical Review of Prospective Trials.
Izmailov T; Ryzhkin S; Borshchev G; Boichuk S
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958408
[TBL] [Abstract][Full Text] [Related]
18. A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions.
Li GJ; Arifin AJ; Al-Shafa F; Cheung P; Rodrigues GB; Palma DA; Louie AV
Ann Palliat Med; 2021 May; 10(5):6045-6051. PubMed ID: 32787370
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Stereotactic Ablative Radiotherapy for Systemic Therapy Respondents with Inoperable Pulmonary Oligometastases and Oligoprogression.
Ho CB; Tsai JT; Chen CY; Shiah HS; Chen HY; Ting LL; Kuo CC; Lai IC; Lai HY; Chung CL; Lee KL; Tzeng HE; Lee KH; Lee HL; Chen SW; Chiou JF
Diagnostics (Basel); 2023 Apr; 13(9):. PubMed ID: 37174988
[TBL] [Abstract][Full Text] [Related]
20. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.
Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF
Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
